Immunohistochemical Analysis of 4-HNE, NGAL, and HO-1 Tissue Expression after Apocynin Treatment and HBO Preconditioning in Postischemic Acute Kidney Injury Induced in Spontaneously Hypertensive Rats.

4-hydroxynonenal acute kidney injury apocynin heme oxygenase-1 hyperbaric oxygen preconditioning neutrophil gelatinase-associated lipocalin oxidative stress

Journal

Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981

Informations de publication

Date de publication:
22 Jul 2021
Historique:
received: 01 06 2021
revised: 15 07 2021
accepted: 16 07 2021
entrez: 27 8 2021
pubmed: 28 8 2021
medline: 28 8 2021
Statut: epublish

Résumé

Oxidative stress has been considered as a central aggravating factor in the development of postischemic acute kidney injury (AKI). The aim of this study was to perform the immunohistochemical analysis of 4-hydroxynonenal (4-HNE), neutrophil gelatinase-associated lipocalin (NGAL), and heme oxygenase-1 (HO-1) tissue expression after apocynin (APO) treatment and hyperbaric oxygenation (HBO) preconditioning, applied as single or combined protocol, in postischemic acute kidney injury induced in spontaneously hypertensive rats (SHR). Twenty-four hours before AKI induction, HBO preconditioning was carried out by exposing to pure oxygen (2.026 bar) twice a day, for 60 min in two consecutive days. Acute kidney injury was induced by removal of the right kidney while the left renal artery was occluded for 45 min by atraumatic clamp. Apocynin was applied in a dose of 40 mg/kg body weight, intravenously, 5 min before reperfusion. We showed increased 4-HNE renal expression in postischemic AKI compared to Sham-operated (SHAM) group. Apocynin treatment, with or without HBO preconditioning, improved creatinine and phosphate clearances, in postischemic AKI. This improvement in renal function was accompanied with decreased 4-HNE, while HO-1 kidney expression restored close to the control group level. NGAL renal expression was also decreased after apocynin treatment, and HBO preconditioning, with or without APO treatment. Considering our results, we can say that 4-HNE tissue expression can be used as a marker of oxidative stress in postischemic AKI. On the other hand, apocynin treatment and HBO preconditioning reduced oxidative damage, and this protective effect might be expected even in experimental hypertensive condition.

Identifiants

pubmed: 34439411
pii: antiox10081163
doi: 10.3390/antiox10081163
pmc: PMC8388865
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Mediators Inflamm. 2015;2015:498405
pubmed: 25972624
Hypertension. 2008 Feb;51(2):211-7
pubmed: 18086956
Cell Stress Chaperones. 2010 Jul;15(4):395-403
pubmed: 19904630
Molecules. 2019 Apr 22;24(8):
pubmed: 31013638
Chem Res Toxicol. 2009 May;22(5):835-41
pubmed: 19388687
Pharmacol Rev. 2008 Mar;60(1):79-127
pubmed: 18323402
Circ Res. 2002 Aug 9;91(3):240-6
pubmed: 12169650
Diabetes Care. 2008 Feb;31 Suppl 2:S170-80
pubmed: 18227481
Proc Natl Acad Sci U S A. 1987 Mar;84(5):1404-7
pubmed: 3029779
J Clin Invest. 2005 Mar;115(3):610-21
pubmed: 15711640
FASEB J. 2005 Nov;19(13):1890-2
pubmed: 16129699
Am J Physiol. 1993 Feb;264(2 Pt 2):F212-5
pubmed: 8447434
Free Radic Biol Med. 1998 Jul 15;25(2):169-74
pubmed: 9667492
Free Radic Biol Med. 2010 Jun 15;48(12):1570-6
pubmed: 20171275
Toxicol Rep. 2015 Aug 04;2:1111-1116
pubmed: 28962452
Int J Biochem Cell Biol. 2009 May;41(5):1025-33
pubmed: 19027871
Cell Death Differ. 2013 Dec;20(12):1615-30
pubmed: 24096871
Int J Mol Sci. 2021 Jan 30;22(3):
pubmed: 33573145
Br J Pharmacol. 1983 Jun;79(2):471-6
pubmed: 6652338
Brain Behav. 2018 Mar 30;8(5):e00959
pubmed: 29761012
Crit Care Res Pract. 2012;2012:691013
pubmed: 23227318
Am J Kidney Dis. 2017 Apr;69(4):531-545
pubmed: 28139396
Mol Cell. 2002 Nov;10(5):1033-43
pubmed: 12453412
Annu Rev Pharmacol Toxicol. 2008;48:463-93
pubmed: 17937594
Adv Chronic Kidney Dis. 2008 Apr;15(2):147-52
pubmed: 18334239
Kidney Int. 2001 Nov;60(5):1858-66
pubmed: 11703604
Vascul Pharmacol. 2016 Dec;87:1-5
pubmed: 27569106
Anesth Analg. 2017 Jan;124(1):204-213
pubmed: 27607480
Exp Ther Med. 2016 Nov;12(5):3175-3180
pubmed: 27882134
J Am Soc Nephrol. 2003 Oct;14(10):2534-43
pubmed: 14514731
J Clin Lab Anal. 2016 Nov;30(6):956-960
pubmed: 27075972
Free Radic Res. 2011 Jul;45(7):810-9
pubmed: 21545264
Int Urol Nephrol. 2014 Aug;46(8):1581-7
pubmed: 24671275
Compr Physiol. 2012 Apr;2(2):1303-53
pubmed: 23798302
Kidney Int. 1998 Mar;53(3):672-8
pubmed: 9507213
Croat Med J. 2012 Dec;53(6):586-97
pubmed: 23275324
Oxid Med Cell Longev. 2017;2017:6193694
pubmed: 29104728
Kidney Int. 1996 Aug;50(2):436-44
pubmed: 8840271
Eur J Clin Invest. 2018 Nov;48 Suppl 2:e12951
pubmed: 29757466
J Am Soc Nephrol. 2004 Dec;15(12):3073-82
pubmed: 15579510
Kidney Int. 2001 Jan;59(1):230-7
pubmed: 11135075
Nephrol Ther. 2012 Dec;8(7):508-15
pubmed: 22541989
Am J Physiol Renal Physiol. 2014 Dec 1;307(11):F1187-95
pubmed: 25350978
Mol Aspects Med. 2008 Feb-Apr;29(1-2):67-71
pubmed: 18158180
Neurol Res. 2007 Mar;29(2):132-41
pubmed: 17439697
Redox Biol. 2015;4:193-9
pubmed: 25598486
Kidney Int. 2004 Aug;66(2):486-91
pubmed: 15253694
Mediators Inflamm. 2008;2008:106507
pubmed: 19096513
Exp Nephrol. 1999 Jan-Feb;7(1):59-62
pubmed: 9892815
Biomolecules. 2015 Sep 30;5(4):2247-337
pubmed: 26437435
Kidney Int. 2013 Jun;83(6):1029-41
pubmed: 23325084
Antioxidants (Basel). 2020 Aug 18;9(8):
pubmed: 32824836
Cell Metab. 2016 Feb 9;23(2):254-63
pubmed: 26777689
Nat Chem Biol. 2010 Aug;6(8):602-9
pubmed: 20581821
Srp Arh Celok Lek. 2007 Nov-Dec;135 11-12:669-71
pubmed: 18368909
Mol Cell Biochem. 2006 Oct;291(1-2):21-8
pubmed: 16625420
Clin Sci (Lond). 2018 May 8;132(9):909-923
pubmed: 29739822
Int J Inflam. 2011;2011:514623
pubmed: 21860805
Int J Mol Sci. 2021 Feb 18;22(4):
pubmed: 33670516
PLoS One. 2020 Jan 8;15(1):e0226974
pubmed: 31914135
Trends Immunol. 2003 Aug;24(8):449-55
pubmed: 12909459
Am J Physiol Cell Physiol. 2016 Oct 1;311(4):C537-C543
pubmed: 27385721

Auteurs

Sanjin Kovacevic (S)

Department of Pathophysiology, Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia.

Milan Ivanov (M)

Department of Cardiovascular Physiology, Institute for Medical Research, University of Belgrade, 11129 Belgrade, Serbia.

Maja Zivotic (M)

Institute of Pathology, Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia.

Predrag Brkic (P)

Department of Medical Physiology, Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia.

Zoran Miloradovic (Z)

Department of Cardiovascular Physiology, Institute for Medical Research, University of Belgrade, 11129 Belgrade, Serbia.

Rada Jeremic (R)

Department of Medical Physiology, Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia.

Nevena Mihailovic-Stanojevic (N)

Department of Cardiovascular Physiology, Institute for Medical Research, University of Belgrade, 11129 Belgrade, Serbia.

Una Jovana Vajic (UJ)

Department of Cardiovascular Physiology, Institute for Medical Research, University of Belgrade, 11129 Belgrade, Serbia.

Danijela Karanovic (D)

Department of Cardiovascular Physiology, Institute for Medical Research, University of Belgrade, 11129 Belgrade, Serbia.

Djurdjica Jovovic (D)

Department of Cardiovascular Physiology, Institute for Medical Research, University of Belgrade, 11129 Belgrade, Serbia.

Jelena Nesovic Ostojic (J)

Department of Pathophysiology, Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia.

Classifications MeSH